September 24th, Switzerland

Free Registration, Part of MipTec 2014, Congress Center Basel


International symposium on geroprotectors:
Practical Applications of Aging Research for Drug Discovery (free registration)

Aging lies at the core of every age-related disease and affects every person on the planet. It represents an unbearable toll on the economies of the developed countries resulting in over two trillion dollars in direct medical costs, costs of caring and lost productivity in the US and EU alone. Yet, pharmaceutical companies fail to see the practical applications of aging research as many early experiments with drugs that held promise in slowing the aging processes resulted in commercial failures and write offs. Lack of business models, regulation and absence of a clear set of aging biomarkers make it difficult for large pharmaceutical companies to fully engage in aging research. Unlike other events that are geared towards academia or have a broad range of topics, this forum intends to focus on drug discovery and pharmaceuticals that may have a role in postponing the aging processes, preventing the age-related diseases and evaluating the effectiveness of various small molecules with geroprotective properties.
The event will showcase the research projects in aging research to the leaders of the pharmaceutical industry. The symposium will comprise into the three sessions relevant to the drug discovery companies. Each session will be chaired by the top expert in the field: 
Session I: Predicting the activity of geroprotective drugs: in-silico screening, omics data analysis and rational drug design
Session II: Drugs with the potential geroprotective properties
Session III: Aging Biomarkers: how do we measure aging and geroprotective efficacy?

Session IV: Trends in Aging Research and Drug Discovery

The forum is part of MipTek 2014, the largest drug discovery conference in Europe attracting over 3,000 delegates from the pharmaceutical industry. 
The forum is organized by:Alex Zhavoronkov, PhD  (The Biogerontology Research Foundation, UK)
Bhupinder Bullar, PhD (Novartis Pharma AG, Switzerland


Post a Comment

Note: Only a member of this blog may post a comment.